# EDGAR Filing Document

**Accession Number:** 0001390478
**File Stem:** 0001104659-26-047697
**Filing Date:** 2026-4
**Character Count:** 5542
**Document Hash:** 39f8cb0dc9f232e817dd55e5abf334a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-047697.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001104659-26-047697

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SELLAS Life Sciences Group, Inc.
- **CENTRAL INDEX KEY:** 0001390478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33958
- **FILM NUMBER:** 26888731

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 6462005278

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Galena Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RXi Pharmaceuticals Corp
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GALENA BIOPHARMA, INC.
- **DATE OF NAME CHANGE:** 20110922

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a)**

**of the Securities Exchange Act of 1934**

Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻

Check the appropriate box:

◻ Preliminary Proxy Statement

◻ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

◻ Definitive Proxy Statement

⌧ Definitive Additional Materials

◻ Soliciting Material Pursuant to § 240.14a-12

**SELLAS LIFE SCIENCES GROUP, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

⌧ No fee required.

◻ Fee previously paid with preliminary materials.

◻ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm261477d3_defa14aimg001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your Vote Counts! SELLAS LIFE SCIENCES GROUP, INC. 2026 Annual Meeting Vote by June 15, 2026 11:59 PM ET You invested in SELLAS LIFE SCIENCES GROUP, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 16, 2026. Vote Virtually at the Meeting\* June 16, 2026 8:30 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/SLS2026 \*Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V86702-P48673 SELLAS LIFE SCIENCES GROUP, INC. 7 TIMES SQUARE, SUITE 2503 NEW YORK, NEW YORK 10036 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by request prior to June 2, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm261477d3_defa14aimg002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". Voting Items Board Recommends V86703-P48673 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. We encourage you to access and review the complete proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. 1. The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders. Nominees: 1a. Robert Van Nostrand For 1b. Jane Wasman For 2. The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve an amendment to the Company's 2023 Amended and Restated Equity Incentive plan (the "2023 Equity Plan") to increase the number of shares of Common Stock authorized for issuance under the 2023 Equity Plan by 20,000,000 shares. For 4. The advisory approval of the compensation of our named executive officers. For 5. The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to adopt the proposals set forth above or to establish a quorum. For |

---